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Abstract: The widely expressed G-protein coupled receptors 
(GPCRs) are versatile signal transducer proteins that are attractive 
drug targets but structurally challenging to study.  GPCRs undergo a 
number of conformational rearrangements when transitioning from 
the inactive to the active state but have so far been believed to adopt 
a fairly conserved inactive conformation. Using 19F NMR spectroscopy 
and advanced molecular dynamics simulations we describe a novel 
inactive state of the adenosine 2A receptor which is stabilised by the 
aminotriazole antagonist Cmpd-1. We demonstrate that the ligand 
stabilises a unique conformation of helix V and present data on the 
putative binding mode of the compound involving contacts to the 
transmembrane bundle as well as the extracellular loop 2. 
G-protein coupled receptors (GPCRs) are a protein family of 
seven-transmembrane (7-TM) receptors that are targeted by a 
greater number of small-molecule drugs than any other single 
family.[1] The adenosine 2A receptor (A2AR) represents a 
promising target for Parkinson’s disease[2]  and drug development 
efforts led to the discovery of Cmpd-1, a dual antagonist to the 
A2AR and the N-methyl D-aspartate receptor subtype 2B (NR2B). 
Cmpd-1, composed of three rings including a central 
aminotriazole, a methylphenyl and a methoxyphenyl, was 
crystallised in complex with the A2AR (Figure 1).[3] The 
methylphenyl and aminotriazole rings of Cmpd-1 occupy a deeply 
buried position similar to the widely-reported bound state of 
antagonist ZM 241385. However, the methoxyphenyl group of 
Cmpd-1 is positioned towards the extracellular aspect of the 
receptor, towards helix I (Figure 1A) and is accompanied by an 
unusual outward movement of helix V (Figure 1B and C).[3] Such 
displacement of helix V has not been observed in any ZM 241385 
bound structures, indeed the phenyl moiety of ZM 241385 points 
almost exclusively towards extracellular loop 2 (ECL2) and the 
solvent (Figure 1C, PDB 5OLG) with one exception - PDB 3PWH, 
where ZM 241385 adopts a binding pose similar to Cmpd-1 but 
intriuingly does not induce a shift in helix V.[4]  
Figure 1. A) Depending on the construct used, the phenyl moiety of ZM 241385 
either points towards ECL2 (grey) or aligns with the methoxyphenyl moiety of 
Cmpd-1 pointing down towards helix I (light green (thermostabilised StaR2), 
light green, with Cmpd-1 in orange).  The common purine motif of the 
endogenous agonist adenosine and NECA (5'-N-Ethylcarboxamidoadenosine) 
is shown in blue, the methoxyphenyl and phenyl moieties of ZM 341285 and 
Cmpd-1 are highlighted in orange. B), C) Superimposing A2AR bound to ZM 
241385 (5OLG[5], grey, StaR2, cytochrome b562-RIL (BRIL) in ICL3 - omitted 
for clarity, and 3PWH[4], light green, StaR2, no ICL3 insert), Cmpd-1 (5UIG[3], 
orange, wild type with BRIL in ICL3) and caffeine (3RFM[4], blue, StaR2, no ICL3 
insert) reveals the unusual outward movement of helix V with Cmpd-1. 
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The unusual orientation of helix V suggests a flexibility in the 
ligand binding pocket with implications for drug development but 
variance in the A2AR constructs used (ICL3 insertions, point 
mutations) means that the interpretation of these conformational 
changes has remained elusive. Here we combined advanced 
molecular dynamics (MD) simulations and nuclear magnetic 
resonance spectroscopy (NMR) to study the binding of Cmpd-1 to 
the A2AR. 19F NMR can be employed to monitor the 
conformational dynamics of GPCRs, revealing multiple active and 
inactive conformations which are then biased by the addition of 
ligands with different efficacy.[6] Combining this with recent 
molecular dynamics (MD) methodologies such as adaptive 
sampling permits a more detailed interpretation of the dynamics 
of ligand binding and receptor conformational states.[7] The A2AR 
in complex with Cmpd-1 was simulated for an aggregated 
simulation time of 12 µs.[8] The first five time-structure 
independent component analysis (tICA) dimensions were 
considered and the projected data was clustered.[9] A fully 
connected Markov state model (MSM) was generated with a 20 
ns lag time and clusters grouped into six macrostates (MS) 
(Figure S1 supporting information).  During the simulation the 
ligand explores the orthosteric site adopting several different 
conformations but did not dissociate. 
 
The macrostates correspond to the crystal bound pose and 
intermediates of the protein-ligand complex (Figure S2, 
supporting information Figure S2) revealing that Cmpd-1 can 
adopt several poses consistent with the low sigma levels of the 
electron density. MS4 and 5 are the two most populated states. 
MS4 corresponds to the crystal bound pose, in which both the 
aminotriazole ring (nitrogen N2) and the amine group of Cmpd-1 
hydrogen bond to N2536.55 [10] located on helix VI. The amine 
group also transiently interacts with E169 and the aminotriazole 
ring with F168 (ECL2, Figure 2). 
 
The additional macrostates might represent “metastable binding 
sites” where Cmpd-1 interacts with different areas of the pocket 
as part of the ligand binding pathway. In MS5, Cmpd-1 interacts 
with ECL2 residues F168 and N154 (ECL2, the F168 interaction 
is also observed in MS 4 and the crystal pose), and with residues 
of helices II and VII (I662.64, S672.65 and L2677.32 as observed in 
the crystal pose, as well as F622.60 and H264 (ECL3)). ECL2 has 
been described in the literature as an important extracellular pre-
recognition site for ligands and the fact that MS4 and 5 are equally 
highly populated underlines the importance of ECL2 in ligand 
recognition (Figure S3, supporting information).[11] The next most 
populated macrostate, MS3, is found to predominantly interact 
with helices I, II, VII. MS2, 1 and 0 are less populated. In MS2, 
Cmpd-1 interacts with ECL2 and helices II, V, VI, while in 
macrostates 1 and 0 the ligand is observed to interact with helices 
I, II, VII and helices II, VI, VII, respectively (Table S1, supporting 
information).  
  
Figure 2. A) Ensemble of poses adopted by Cmpd-1 in the orthosteric site. The 
poses are colour-coded violet, green, pink, yellow, silver and cyan for MS5, 4, 
3, 2, 1 and 0 respectively. Left: The detailed Cmpd-1/receptor interactions in 
macrostate 5 and 4 highlighting residues within 4 Å of the ligand highlighted. B) 
Helix V conformation in MS5 (white) aligned with the structure 5UIG bound to 
Cmpd-1 (orange) and 3RFM bound to caffeine (blue). Dashed lines indicate 
distances between I1063.54 and K2095.70 located on helices III and V, 
respectively. The average distance of MS5 is 22 ± 1 Å (black line) whereas it is 
15.8 Å in the Cmpd-1 crystal structure (orange) and 10.7 Å for the caffeine-
bound structure (blue).  
In the A2AR-Cmpd-1 structure, the displacement of helix V creates 
space for R1073.55 on helix III to form an ionic lock with Glu2286.30 
on helix VI. This interaction is homologous interaction to the lock 
reported in rhodopsins but involves R1073.55 rather than R1023.50. 
To exclude the influence of crystal artifacts, we monitored the 
average distance between the Cα atoms of residue I1063.54 on 
helix III and K2095.70 on helix V as well as the average distance 
between residues Glu2286.30 and R1073.55. Distances were 
extracted for 500 randomly chosen frames (structures) from each 
macrostate (Figures S4 and S5 supporting information). Helix V 
shows an outward displacement in each of the macrostates with, 
on average, a distance of 20 ± 0.8 Å between I1063.54 and K2095.70 
whereas this distance is 15.8 Å in the A2AR-Cmpd-1 structure and 
10.7 Å in A2AR-caffeine.[4] Only MS5 shows a greater average 
distance of 22 ± 1 Å.  Strikingly the Glu2286.30 and R1073.55 
interaction is especially stable in macrostate 5 (1.70 ± 0.1 Å) 
versus 3.65 Å in the A2AR/Cmpd-1 structure. The interaction is 
also preserved in MS4 (3.6 ± 2.1 Å) and MS 1 and 2 but reaches 





~ 4.9 and 5.0 Å in MS0 and 3 respectively (ensemble average is 
3.7 Å). All values are lower than the 7.8 Å distance observed in 
the caffeine-bound state although the distance fluctuations are 
larger than those observed in MS5.   
 
We further validated these observations using NMR [6a] and chose 
to introduce an 19F label in K2095.70 to monitor the flexibility of helix 
V by directly observed 19F NMR. K2095.70 was selected as it is not 
conserved in class A GPCRs (see supporting information Figure 
S6). As a control, we used V2296.31C described previously to 
detect conformational changes of helix VI.[6] Receptor 
functionality of the K2095.70C and V2296.31C mutants did not alter 
receptor-ligand binding affinities (supporting information Figure 
S7, table S2). 
 
The A2AR was tagged using described protocols[6b] and NMR 
spectra of 19F tagged V2296.31C and K2095.70C in the presence of 
ZM 241385, caffeine, NECA and Cmpd-1 were recorded (Figure 
3, supporting information table S3). In the V2296.31C control, ZM 
241385, caffeine and Cmpd-1 all yielded a dominant signal with a 
19F chemical shift at or close to -61.08 ppm consistent with helix 
VI being stabilised in an inactive state.[6b] This consistent 
response to three antagonists provides further validation that the 
19F tag reliably reports the nature of the ligand – presumably via 
a similar conformation of Helix VI.[6b] Unlike previous reports, 
however, the three antagonists resulted in only minor peaks at the 
chemical shift attributed to the partially active state (S3) (-61.55 
ppm, Figure 3). The shift to a predominance of the inactive state 
may arise from differences in detergent/cholesterol 
composition[6b] and DMSO concentrations. Binding to NECA, a full 
agonist and analogue of the physiological ligand, resulted in the 
expected upfield shift of the 19F signal which has been described 
as resulting from a partially active conformation of helix VI.[6b] 
 
When monitoring the conformation of helix V using the probe at 
K2095.70C, both ZM 241385 and caffeine antagonists result in an 
almost identical 19F chemical shift (Figure 3). The full agonist 
NECA resulted in a downfield chemical shift, which is distinct from 
the ZM 241385 and caffeine induced inactive form and the upfield 
chemical shift of the helix VI tag in the active conformation. 
Strikingly however, Cmpd-1 gives rise to a distinct upfield 19F 
chemical shift that is distinguishable from both the antagonists 
and the agonist (Orange, Figure 3B). This is consistent with the 
Cmpd-1 induced shift of helix V of A2AR detected in both the X-
ray structure and MD simulations. It is also important to note that 
the 19F NMR signals we report here have been observed in A2AR 
that is free from thermostabilising mutations or insertions aside 
from the V2096.31C mutation. 
 
To explore solvent exposure effects MD simulations were derived 
from published crystal structures of the A2AR bound to ZM 
214835 and Cmpd-1 built with the BTFMA tag on the K209C5.70 
site. Trajectories were produced over 625 ns for each coordinate 
set and the solvent exposure of the tag was analysed. The 
analysis shows that 19F nucleus samples conformations with 
greater solvent exposure in the Cmpd-1 bound trajectories 
(Supporting Information Figure S8). This is consistent with the 
published rationalisation of the 19F chemical shift on V2296.31C site 
where increased electronic shielding was linked to solvent 
exposure.[6b, 12]  
 
Figure 3. A) Normalised 19F NMR spectra of V2296.31C. A similar 19F chemcial 
shift is observed when A2aR is exposed to three different antagonists, distinct 
from the agonist NECA B) 19F NMR spectra of K2095.70C. Cmpd-1 causes the 
receptor to report a distinct state.  
Cmpd-1 was developed as a dual antagonist of the A2AR and 
NR2B to improve motor function in Parkinson’s disease.[3] It is 
generally accepted that the GPCR antagonists function by 
stabilising an inactive form of the receptor, through a combination 
of ligand-receptor interactions and intra-receptor contacts (e.g. 
the ionic lock). The ionic lock at the intracellular face of the 
receptor is a well described feature of the inactive state of GPCRs. 
The salt-bridge is generally formed by a positively charged 
residue on helix III in position 3.50 and a negatively charged 
residue on helix VI in position 6.30.[13] The ionic lock has been 
reported for A2AR between residues E2286.30 and R1023.50 
although this depends on the thermostable receptor utilised in the 
crystallographic studies.[4] Cmpd-1 induces not only the unusual 





outward tilt of helix V but also introduces an alternative ionic lock 
between E2286.30 and R1073.55 which was attributed to the 
methoxyphenyl moiety interacting with an extended orthosteric 
pocket (Figure S8).[3] Our analyses have shed light on the 
conformers that comprise this inactivated state and provided 
evidence that the helix V shift and the new ionic lock are stable 
and linked to the pose of Cmpd-1. The highly populated MS4 
captures each of these features of the X-ray structure of A2aR-
Cmpd-1. Further, the pose adopted by Cmpd-1 in the most highly 
populated MS5 increases the outward movement of helix V to 22 
Å and shortens the Glu2286.30 - R1073.55 distance to 1.7 ± 0.1 Å. 
This suggests that the displacement of helix V correlates with the 
strength of the ionic lock. In the remaining less stable states, the 
ionic interaction is transient or broken (eg macrostates 3 and the 
minor state 0 show an average of 5.07 ± 0.7 and 4.9 ± 0.6 Å 
respectively versus the ensemble average of 3.7 ± 0.1 Å) with little 
correlation to Helix V movement.   
 
NMR studies have previously presented evidence for the inactive 
state arising from exchange between two conformers where the 
canonical ionic lock is either made or broken. The exchange 
between these states, termed S1-2 is fast enough on the NMR 
timescale to give rise to only a single 19F signal in tagging 
experiments of A2AR.[6b, 14] If binding of Cmpd-1 generates 
exchange between MS4 and 5 these too are presumably fast 
enough on the NMR timescale to generate a single 19F resonance, 
albeit distinguishable in chemical shift from that of other 
antagonists tested.[14b]  
  
Figure 4. Comparison of A2AR in complex with Cmpd-1 in MS5 (light blue) 
representing sampling of the proposed metastable site and the crystal 
structures of Cmpd-1 (orange), MS4 (bright green) and antagonist ZM241385 
(light green) which collectively show occupancy of the A2AR orthosteric site and 
extended orthosteric site.  
In previous studies, compounds have been observed to visit 
analogous extracellular metastable positions, described as GPCR 
allosteric sites. Amongst GPCR sub-types these sites are defined 
by non-conserved residues whereas orthosteric sites are more 
highly conserved (Figure 4, supporting information Figure S6, 
table S1 in supporting information). It is thought, therefore, that 
these regions which lie close to the orthosteric site could be 
responsible for ligand specific effects and may impart 
selectivity.[15] Cmpd-1 exchanges between equally populated 
MS4 and 5 and thus occupy an extended orthosteric site and a 
metastable allosteric site with equal probability.[16] Modification of 
the orthomethoxyphenyl ring of Cmpd-1 led to loss of potency and 
selectivity for A2AR versus A1R that underlined the importance of 
the extended orthosteric site.[3] However, the binding to the 
extended orthosteric site, although important, might be only part 
of the binding picture. In this study MD simulations have captured 
binding to the extended orthosteric site as well as a metastable 
allosteric site and it is tempting to speculate that the combination 
of these interactions drives the receptor selectivity.[17]   
 
In summary, the combination of adaptive sampling molecular 
dynamics with 19F-NMR spectroscopy verifies the unusual A2AR 
conformation induced by Cmpd-1. We identified metastable 
binding sites for this aminotriazole compound and provide a 
possible rationalization for the unique conformation of A2AR with 
Cmpd-1. Recent spectroscopic studies have described the 
conformational flexibility of GPCRs and identified different 
conformations a GPCR adopts when transitioning from the 
inactive to the active state.[14b] The unique inactive state 
supported by this study suggests that the GPCR conformational 
landscape may be more complex. Furthermore, this study reveals 
that Cmpd-1 can bind to a metastable allosteric site. This exciting 
discovery may open up new possibilities for optimising A2AR 
ligand selectivity by targeting the non-conserved residues that 
delineate the allosteric pocket. 
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Materials and Methods  
Adaptive sampling and system setup 
Taking the crystal structure of A2A in complex with the aminotriazole antagonist (Cmpd-1) (pdb 
code 5UIG), a completed human model of A2A was built and used to initiate the MD 
simulations.[1] The 5UIG structure was first edited to remove b62-RIL and a model was 
constructed by modelling in the extracellular loop 2 (ECL2) residues (146-165) and the C-
terminal aspect (from Phe295 onwards) of the A2A structure 4EIY using Prime.[2] These steps 
were necessary as the ECL2 residues were not well defined in the 5UIG structure and the C-
terminal segment from Phe295 onwards appeared be perturbed in 5UIG. The absent intracellular 
loop 3 (ICL3) of the 5UIG structure was modelled using the MEDELLER protocol,[3] the core of 
which is a membrane-protein-specific version of PyFREAD for fragment-based loop modelling,[4] with 
missing sidechains modelled using SCWRL3[5] and clashes removed using MODELLER.[6] The template 
for the missing loop was the ICL3 loop taken from the A2A structure 3VG9 (ref). The structure 
was then treated using the Protein Preparation Wizard in Maestro to add hydrogens and 
determine the appropriate protonation states of the ionizable residues.[7] The structure was then 
prepared for simulation.[8] The ligand was parameterized with the HTMD parameterize version 
1.9.7. The CHARMM36 force field was used and the protein was simulated in a pre-equilibrated 
80X80 POPC bilayer, supplemented with 20% of cholesterol.[9] TIP3P water molecules were 
used to solvate the system together with Na+ and Cl- ions to obtain an ionic strength of 0.15 M. 
ACEMD was used with the hydrogen mass repartitioning scheme to run the simulations on GPUs 
with a time-step of 4 fs.[10] The system was first minimized with 500 steps of conjugated gradient 
and then equilibrated at 300 K using an NPT ensemble with a Berendsen barostat at 1 atm for 
100 ns. During the equilibration heavy atoms of ligand, protein and lipids were constrained by a 1 
kcal/mol/Å2 spring constant and gradually released. Particle mesh Ewald was used for handling 
long-range electrostatic interactions with a cutoff of 9.  
 
The simulations were run using the adaptive sampling protocol implemented in HTMD on a 
dedicated GPU cluster. Simulations of the A2A-ligand complex were carried out in an NVT 
ensemble for an aggregated time of 12 μs. 
 
Adaptive sampling setup 
Adaptive sampling takes advantage of Markov state models (MSM) to analyse MD trajectories on 
the fly and select for frames to initiate a new round of simulations, allowing an enhanced 
exploration of complex phenomena.[11] Markov state models (MSM) are then applied to analyse 
the individual trajectories and to select for frames used to initiate a new round of simulations. 
Each round is referred to as an epoch and typically several epochs are run per study. The 
epochs are seeded with a selection of frames that are chosen using pre-defined geometric 
descriptors. In this study, protein dihedral angles were used as they represent general 
descriptors of protein conformational change.[12] Importantly, the adaptive sampling protocol does 
not add any bias to the simulation. 
MSM generation 
The conformational space of the A2A receptor in complex with Cmpd-1 was discretized by 
considering a contact map of the interactions between the ligand heavy atoms, not attached to 
   
 
   
 
hydrogens, and all protein atoms. A threshold of 5 Å was used to discriminate the residues not in 
contact with the ligand, those at a higher distance than 5 Å.  
 
Time-structure independent component analysis (TICA) was used to identify the slowest 
processes and subsequently the contact map previously defined was projected on the first five 
TICA dimensions.[13] The projected data was then clustered using the mini batch k-means 
algorithm in 272 clusters.[14] The MSM was generated at 20 ns lag time and clusters were lumped 
into 6 macrostates using the PCCA algorithm.[15]  
 
Distances between residues were measured between their center of mass, e.g. residues Glu2286.30 
and R1073.55. 
 
Sequence conservation analysis 
The sequence of the 5UIG X-ray structure was used to search in the Pfam webserver for existing 
alignments. One alignment for the 7tm_1 family was obtained containing 64 sequences. The 
corresponding HMM logo was downloaded.  
 
Ligands: ZM 241385, Caffeine, Theophylline, and NECA were purchased from Sigma Aldrich 
 
Construct: A construct containing amino acids 1-316 with N154Q to prevent N-linked 
glycosylation was synthesised (ATUM), flanked with TEV protease sites, an N-terminal 
TwinStrepII and a C-terminal 10His tag. Single point mutations were introduced using the 
QuickChange Lightning kit (Agilent). All constructs were sequence verified.  
 
Expression and Membrane Preparation: The A2AR was expressed in expi293 cells after 
standard transfection using the ExpiFectamine 293 kit according to manufacturer’s instructions 
(ThermoFisher). Cells were harvested 48 h post-transfection, flash frozen in liquid nitrogen and 
stored at – 80 C until further use. All subsequent steps were performed on ice or at 4 °C. Cells 
were resuspended in lysis buffer (25 mM HEPES, 1 mM ethylenediaminetetraacetic acid (EDTA), 
100 µM theophylline (omitted for radioligand assay membranes), pH 7.4 + complete EDTA-free 
protease inhibitors (PI, Roche) and lysed by two passes through a continuous cell disruptor (11.0 
kpsi (Constant Systems). Debris was removed by centrifugation (7000 g, 20 min). Membranes 
were spun down (187945 x g, 1 h 30 min) washed by re-suspension in ice-cold high salt buffer 
(25 mM HEPES, 500 mM NaCl, 1 mM EDTA, 100 µM theophylline, pH 7.4 +PI), spun down 
again (187945 x g, 1 h 30 min, 4 C) and re-suspended in ice cold storage buffer (PBS, 10% 
glycerol, 100 µM theophylline, pH 7.4, +PI), before being flash frozen in liquid nitrogen and 
stored at -80 until purification. 
A2A Purification and Tagging: Membranes were solubilised (0.5% LMNG (Anatrace), 0.1% 
CHS, 3 h) at 5 mg/ml total protein concentration as determined by bicinchoninic acid assay 
(BCA). Insoluble matter was removed by ultracentrifugation (187945 x g, 1 h) and the 
supernatant was incubated with buffer-equilibrated TALON Superflow (GE Healthcare) slurry 
overnight. The flow-through (FT) was separated on a 2 ml gravity flow column. The resin was 
washed with 10 CV buffer A (50 mM HEPES, 100 mM NaCl, 10% glycerol + 0.01% LMNG + 
0.002% CHS, pH 7.4), 10 CV buffer B (50 mM HEPES, 800 mM NaCl, 20 mM imidazole, 10 mM 
MgCl2, 10 % glycerol + 0.01% LMNG + 0.002% CHS, pH 7.4). The immobilised protein was then 
incubated with 4 CV buffer A + 100 µM TCEP (20 min) and the buffer was removed immediately 
at the end of the incubation and washed with 20 CV buffer A. The beads were incubated with 100 
µM BTFMA (6 h, with agitation), then 150 µM fresh BTFMA was added and the beads were 
washed with 10 CV buffer A (50 mM HEPES, 100 mM NaCl, 10% glycerol + 0.01% LMNG + 
0.002% CHS, 4 °C, pH 7.4) after overnight incubation. Protein was eluted with 8 CV buffer E (50 
mM HEPES, 100 mM NaCl, 10% glycerol, 200 mM imidazole, 4 °C, pH 7.4), concentrated as 
required (50 kDa cut-off, Amicon) and desalted in a 3 ml PD10 column (GE Healthcare) into 
buffer A. 
TEV Digest: The protein was treated with TEV protease expressed in house (1:1 TEV to A2AR 
mass ratio, 4 h, 4°C) and subsequently incubated with 1 ml equilibrated TALON Superflow bead 
   
 
   
 
slurry per mg TEV overnight and the FT containing A2A was collected. A2A was desalted into 
buffer SG (50 mM HEPES, 100 mM NaCl, 0.01 % LMNG, 0.002% CHS, pH 7.4). 
Radioligand Binding Assays on Membranes: Membranes were prepared as for purification 
but without the addition of theophylline in the storage buffer. Membrane samples containing 10 
µg total protein were incubated with 0.4 nM [3H] ZM 241385 with a final concentration of 0.1% 
DMSO in buffer R (50 mM Tris-HCl, 2 mM MgCl2, pH 7.4) for 1 hour at room temperature (n = 6). 
The reactions were terminated by rapid filtration over glass fibre filters and washed with 50 mM 
Tris (pH 7.4) using a Skatron Harvester. Remaining scintillation was counted in a PerkinElmer 
1450 Microbeta plate reader. 
Radioligand Binding Assays on Purified Receptor: Purified A2AR was incubated at 0.01 
mg/ml with 50 nM [3H] ZM 241385 (n = 3) for 1 hour at room temperature, unbound ligand was 
removed on a Zeba desalting column and bound ligand was counted in a PerkinElmer Tricarb 
2910 TR Liquid Scintillation Analyser. Non-specific binding was measured by in the presence of 
20 µM ZM 241385 (n= 3). All binding data were analysed with GraphPad Prism 6. 
NMR: Samples of cleaved and tagged A2A were made up at a concentration of 20 µM (measured 
by BCA) in buffer SG with 2% DMSO and the relevant ligand in a D2O-matchced Shigemi tube. 
Samples were doped with 10% D2O.  All experiments were run on a Bruker AVIII HD 
spectrometer operating at a magnetic field strength of 14.1 T equipped with a 5 mm QCI-F 
Helium Cooled Cryoprobe. The experiments were run detecting 19F with a spectral width of 138 
ppm, 490 ms acquisition time, a recycle delay of 1 s, 15 000 scans, at a temperature of 298.2 K 
and processed with 15 Hz of line broadening.  
Coordinate Preparation for Solvent Exposure MD: The X-ray crystal structures of Cmpd-1 
and ZM 241385 bound complexes of the A2A receptor (PDB: 5UIG and 5IU4 respectively)[1, 16] 
from the Protein Data Bank were prepared using Chimera (1.12, UCSF) as follows. Cytochrome 
b562RIL fused into intracellular loop 3 (ICL 3) of the antagonist bound structure (PDB: 5IU4) was 
removed and replaced by coordinates of the loop and flanking helical residues from another A2A 
structure bound to the antagonist ZM 241385 (PDB: 3VG9).[7] Helices V and VI were completed 
from 5IU4 and the remaining loop region build using Modeller[6] and an appropriate conformation 
was chosen by visual inspection of the top 5 modelled loops. For the 5IU4 structure 
thermostabilising mutations were reverted to the wild type sequence (A54L2.52, T88A3.36, 
R107A3.55, K122A4.43, L202A5.63, L235A6.37, V239A6.41, and S277A7.42). The N154A mutation 
which is included in expression constructs to remove a putative glycosylation site was also 
reverted to wild type for the simulations. Each set of A2A coordinates was embedded in a 
POPC:POPE:cholesterol lipid bilayer with a ratio of 5:5:1 by replacement using the CHARMM-
GUI membrane builder.[17] The cysteine point mutations V229C and K209C were inserted and 
the BTFMA 19F tag was built on in chimera.  Hydrogen atoms were added consistent with pH 7 
and the protein and lipid parameterised with the Amber ff14SB[18] and Lipid14[19] forcefields 
respectively. The simulation box had initial dimensions of 85 Å, 85 Å, 120 Å solvated in TIP3P 
water and 0.15 M NaCl. The BTFMA fluorine tag, ZM 241385 and Cmpd-1 were parameterised 
using Antechamber and the general Amber forcefield.[20] Amber parameter and topology files 
were prepared using LEaP. 
MD simulation for solvent exposure: Structures were minimised for 10000 steps. All 
simulations were performed under periodic boundary conditions with a 2 fs integration time step 
and long-range electrostatics treated with the PME method. Simulations were initiated by heating 
from 0 to 100 K over 5 ps in 2500 steps and from 100 K to 303 K over 100 ps in 50000 steps as 
NVT ensembles. The box dimensions were equilibrated over 10 rounds of 500 ps simulation for 
250000 steps each as NPT ensembles. Simulations were run for 125 ns each (62.5 x 106 MD 
steps) with the trajectory file printed every 5000 steps. Temperature and pressure were 
controlled using the Langevin thermostat and the Monte Carlo barostat respectively.  The 
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Figure S1: Implied Bayesian timescales of the generated MSM model. Each line 
corresponds to a relaxation timescale for the considered system. The final model was built at 
20 ns lag time.  
 
   
 
   
 
 





   
 
   
 
 
Figure S3: Equilibrium distribution plot obtained for the generated MSM model. Six kinetic 
macrostates were extracted and the respective equilibrium probabilities are as follows: 







   
 
   
 
 
Figure S4: Distance between I106 (helix III) and K209 (helix V). The average distance and 
the relative standard deviation have been calculated over 500 frames for each macrostate 
(black dashed line). In all plots the reference values for 5uig (red dashed line) and 3rfm 
(green dashed line) are reported. The average distance of the conformational ensemble is 
20.28 Å.  
   
 
   
 
 
Figure S5: Distance between R107 (helix III) and E228 (helix VI). The average distance and 
the relative standard deviation have been calculated over 500 frames for each macrostate 
(black dashed line). In all plots the reference values for 5uig (red dashed line) and 3rfm 
(green dashed line) are reported. The average distance of the conformational ensemble is 
3.7 Å. 
   
 





Figure S6: HMM sequence logo of 7 helix transmembrane receptors family (7tm_1). The 
dimension of the residue name corresponds to the level of conservation (the more 
conserved, the bigger is the letter). The amino acid position of the tag is marked with an 
arrow. The residues interacting with Cmp-1 in macrostate 5 are marked with an “M5” flag. 
 
 
   
 







Figure S7. Competition binding experiments for each ligand against [3H] ZM 241385. 
Introducing cysteine residues at K3095.70 and V2296.31 does not significantly change the 
affinity of the respective ligands for the receptor. Data is represented as means ± SEM from 
two separate experiments performed in triplicate (n=6). 
 
   
 




Figure S8: Solvent exposure of the fluorine atom of the BTFMA tag on V2296.31C and 
K2095.70C when bound to ZM 241385 and Cmpd-1, respectively. The data for coordinate 
sets containing Cmpd-1 are shown in orange and those for ZM 241385 are shown in blue. 
The 19F atoms tagged on ZM 241385-bound A2AR and those on V2296.31C with Cmpd-1 are 
not able to sample solvent exposures of above 100 Å2 to the same extent as the 19F atoms 
tagged on K2095.71C with Cmpd-1. These data are consistent with the distinct chemical shift 
of K2095.70C-BTFMA bound to Cmpd-1 seen in the NMR spectra. 
 
  
   
 





















VII EL1 EL2 EL3 
0 20±0.7 4.9±0.6 + +    + +    
1 20±0.8 3.6±2 + +     +    
2 20±0.8 3.3±1.75  + +  + +   +  
3 19.8±0.8 5.07±0.7 + +    + +    
4 19.9±0.9 3.6±2.1  + +  + + +  +  
5 22±1 1.70±0.1  +     + + + + 
 
Table S1: For each macrostate are listed: the distance between residues I106 (helix III) and 
K209 (helix V), the distance between residues R107 (helix III) and E228 (helix VI) and with a 
+ are marked the helices that interact with Cmpd-1. Common contacts are highlighted in 
orange (helix II), contacts for macrostates 5 and 4 are highlighted in green and contacts 
unique to macrostate 5 are highlighted in blue. 
 
 Wild type V2296.31C K2095.70C 
ZM 241385 7.79 ± 0.11 7.75 ± 0.16 7.84 ± 0.14 
Cmpd-1 6.86 ± 0.15 6.98 ± 0.13 6.93 ± 0.17 
Caffeine 4.12 ± 0.12 4.36 ± 0.122 3.89 ± 0.22 
NECA 6.12 ± 0.14 6.55 ± 0.22 6.11 ± 0.19 
 









Table S3: 19F chemical shift data (d/ppm) for both V2296.31C and K2095.70C in the presence 
of antagonists/agonists 
 V2296.31C K2095.70C 
NECA 61.55 60.09 
Caffeine 61.06 61.12 
ZM 241385 61.06 61.13 
Cmpd-1 61.06 61.26 
